Therapeutic effects of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis

Background and purpose: Outcomes for cancer patients with steroid-resistant immune checkpoint inhibitor-associated myocarditis (srICIAM) are poor. Intensified immunosuppressive therapies, including tofacitinib, a novel Janus kinase (JAK) inhibitor, may have some therapeutic benefits. However, due to...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Yuchen XU, Jian ZHANG, Yan WANG, Jinyi LIN, Yuhong ZHOU, Leilei CHENG, Junbo GE
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Editorial Office of China Oncology 2024-04-01
Цуврал:	Zhongguo aizheng zazhi
Нөхцлүүд:	Immune checkpoint inhibitors Immunotherapy Myocarditis Janus kinase inhibitor
Онлайн хандалт:	http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2024.04.007
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!